热门资讯> 正文
拉斐尔制药公司胆道癌联合治疗试验增加地点
2022-01-19 00:56
11:51 AM EST, 01/18/2022 (MT Newswires) -- Rafael Pharmaceuticals (RFL) said Tuesday it plans to open additional sites for its mid-stage biliary tract cancer clinical trial amid "the ongoing successful enrollment rate."
The phase 2 trial for prospective treatment CPI-613, known generically as devimistat, in combination with gemcitabine and cisplatin is adding seven sites to the three already enrolling patients with locally advanced unresectable or metastatic biliary tract cancer who have had no prior treatment, Rafael said.
Shares were down 4.4% in recent Tuesday trading.
Price: 4.75, Change: -0.22, Percent Change: -4.43
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
